%0 Journal Article
%A Jessen, Frank
%A Arbizu, Javier
%A Boada, Mercé
%A Balasa, Mircea
%A Bennys, Karim
%A Boban, Marina
%A Bürger, Katharina
%A Chincarini, Andrea
%A Cagnin, Annachiara
%A De Deyn, Peter Paul
%A Düzel, Emrah
%A Engelborghs, Sebastiaan
%A Ewers, Michael
%A Exalto, Lieza G
%A van der Flier, Wiesje M
%A Fortea, Juan
%A Frederiksen, Kristian Steen
%A Frisoni, Giovanni B
%A Frölich, Lutz
%A Garza-Martinez, Alejandro J
%A Grimmer, Timo
%A Hanseeuw, Bernard
%A Hort, Jakub
%A Ivanoiu, Adrian
%A Kehoe, Patrick G
%A Kennelly, Sean P
%A Kern, Silke
%A Klöppel, Stefan
%A Krajčovičová, Lenka
%A Kramberger, Milica G
%A McGuinness, Bernadette
%A Mecocci, Patrizia
%A Oberstein, Timo Jan
%A Ousset, Pierre-Jean
%A Paquet, Claire
%A Perneczky, Robert
%A Piazza, Fabrizio
%A Plantone, Domenico
%A Rainero, Innocenzo
%A Sacco, Guillaume
%A Salmon, Eric
%A Santana, Isabel
%A Scarmeas, Nikolaos
%A Schneider, Anja
%A Schott, Jonathan M
%A Solje, Eino
%A Stefanova, Elka
%A Stögmann, Elisabeth
%A Strauss, Mélanie
%A Sutovsky, Stanislav
%A Waldemar, Gunhild
%A Winblad, Bengt
%T Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.
%J The journal of prevention of Alzheimer's disease
%V 12
%N 8
%@ 2274-5807
%C Cham
%I Springer International Publishing
%M DZNE-2025-01078
%P 100259
%D 2025
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40640062
%R 10.1016/j.tjpad.2025.100259
%U https://pub.dzne.de/record/281117